1	Epidemiological and clinical features of SARS-CoV-2 Infection in children during
2	the outbreak of Omicron Variant in Shanghai, March 7-March 31, 2022
3	Xiangshi Wang <sup>1,</sup> <sup>†</sup> , Hailing Chang <sup>1,</sup> <sup>†</sup> , He Tian <sup>1,</sup> <sup>†</sup> , Jingjing Li <sup>1</sup> , Zhongqiu Wei <sup>1</sup> , Yixue Wang
4	<sup>2</sup> , Aimei Xia <sup>1</sup> , Yanling Ge <sup>1</sup> , Jiali Wang <sup>1</sup> , Gongbao Liu <sup>3</sup> , Jiehao Cai <sup>1</sup> , Jianshe Wang <sup>1</sup> , Qirong
5	Zhu <sup>1</sup> , Yanfeng Zhu <sup>1,*</sup> , Xiaowen Zhai <sup>4,*</sup> , Mei Zeng <sup>1,*</sup>
6	
7	<sup>1</sup> Department of infectious diseases, Children's Hospital of Fudan University, National
8	Children's Medical Center
9	<sup>2</sup> Department of intensive care medicine, Children's Hospital of Fudan University, National
10	Children's Medical Center
11	<sup>3</sup> Department of medical affairs, Children's Hospital of Fudan University, National Children's
12	Medical Center
13	<sup>4</sup> Department of Hematology, Children's Hospital of Fudan University, National Children's
14	Medical Center
15	† Xiangshi Wang, Hailing Chang and He Tian equally contributed to this paper.
16	* Address for correspondence:
17	Yanfeng Zhu, MD, PhD, Department of Infectious Diseases, Children's Hospital of Fudan
18	University, 399 Wanyuan Road, Shanghai 201102, China. E-mail: smilingyf@sina.com, Tel:
19	86-021-64931132 (office), 86-13916913420 (mobile).
20	Xiaowen Zhai, MD, PhD, Department of Hematology, Children's Hospital of Fudan University,
21	399 Wanyuan Road, Shanghai 201102, China. E-mail: zhaixiaowendy@163.com, Tel: 86-021-
22	64931902 (office), 86-18017590808(mobile).
23 NC	Mei Zeng, MD, PhD, Department of Infectious Diseases, Children's Hospital of Fudan DTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 24 University, 399 Wanyuan Road, Shanghai 201102, China. E-mail: zengmeigao@163.com, Tel:
- 25 86-021-64931132 (office), 86-15000284050 (mobile).
- 26
- 27 Abstract
- 28 **Objectives**: To understand the epidemiological and clinical characteristics of pediatric SARS-CoV-2
- 29 infection during the early stage of Omicron variant outbreak in Shanghai.
- 30 Methods: This study included local COVID-19 cases <18 years in Shanghai referred to the exclusively
- 31 designated hospital by the end of March 2022 since emergence of Omicron epidemic. Clinical data,
- 32 epidemiological exposure and COVID-19 vaccination status were collected. Relative risks (RR) were
- 33 calculated to assess the effect of vaccination on symptomatic infection and febrile disease.
- 34 **Results**: A total of 376 pediatric cases of COVID-19 (median age:6.0±4.2 years) were referred to the
- designated hospital during the period of March 7-31, including 257 (68.4%) symptomatic cases and 119
- 36 (31.6%) asymptomatic cases. Of the 307 (81.6%) children;3 years eligible for COVID-19 vaccination,
- 37 110 (40.4%) received 2-dose vaccines and 16 (4.0%) received 1-dose vaccine. The median interval
- 38 between 2-dose vaccination and infection was 3.5 (IQR: 3, 4.5) months (16 days-7 months). Two-dose
- 39 COVID-19 vaccination reduced the risks of symptomatic infection and febrile disease by 35% (RR 0.65,
- 40 95% CI:0.53-0.79) and 33% (RR 0.64, 95% CI: 0.51-0.81). Two hundred and sixteen (83.4%)
- 41 symptomatic cases had fever (mean duration: 1.7±1.0.8 days), 104 (40.2%) had cough, 16.4% had
- 42 transient leukopenia; 307 (81.6%) had an epidemiological exposure in household (69.1%), school (21.8%)
- 43 and residential area (8.8%).

44 Conclusion: The surge of pediatric COVID-19 cases and multiple transmission model reflect wide
45 dissemination of Omicron variant in the community. Asymptomatic infection is common among

- 46 Omicron-infected children. COVID-19 vaccination can offer protection against symptomatic infection
- 47 and febrile disease.

## 48 Introduction

49	The COVID-19 pandemic has caused devastation to the world's population, resulting in more than
50	6 million deaths as of April 20, 2022. SARS-CoV-2 infection in most pediatric cases is mild as compared
51	to adults and the direct effect on child health is limited [1]. However, the indirect impacts on child medical
52	care, education and mental health are considerable owing to lockdown, disruption of essential health
53	service delivery, prolonged school closure and isolation [2,3]. The continuous genetic evolution of
54	SARS-CoV-2 virus results in the emergence of multiple new variants of concern (VOC), which are
55	associated with enhanced transmissibility or increased virulence and immune escape [4]. The Omicron
56	variant, which was detected in November 2021 and almost replaced Delta variant by the end of January
57	2022, has led to the fifth global wave of COVID-19 epidemic [5]. The significant rise of pediatric
58	infection was reported in the United States with children aged <18 years, representing 17.0%-19.0% of
59	all cases during the Omicron period since late December 2021 [6,7].
60	Pediatric COVID-19 cases only accounted for a small proportion of infection in the early stages of
61	the COVID-19 pandemic when many countries implemented non-pharmaceutical interventions and strict
62	containment measures [8-12]. However, the incidence rate of COVID-19 in children showed a rising
63	trend in the epidemic countries following suspension of lockdown and school reopening [12,13]. After
64	the large-scale epidemic in early 2020, China entered a normalization stage of prevention and control,
65	and massive COVID-19 vaccination campaign was launched nationwide in 2021. Inactivated SARS-
66	CoV-2 vaccine BBIBP-CorV (by Sinopharm) and CoronaVac (by Sinovac) were approved for emergency
67	use in children 3-17 years on June 2021 and COVID-19 vaccination program was initiated in pediatric
68	population since late July 2021 across China. From May 2020, local pediatric COVID-19 infection linked
69	to sporadic and cluster transmission were occasionally reported in China until the community outbreak

70	of Omicron variant appeared in Hong Kong Special Administrative Region since January 6, 2022 and
71	subsequently in Shanghai since early March 2020 [14]. Omicron variant spread rapidly in Shanghai by
72	the end of March and led to a surge of pediatric COVID-19 cases citywide. Here, we describe
73	epidemiological and clinical characteristic of Omicron variant infections in Shanghainese children during
74	the early stage of the outbreak.
75	
76	Subject and Method
77	Subject
78	In this study, we included local COVID-19 cases <18 years of age who were notified in Shanghai
79	and admitted to the exclusively designated hospital in Shanghai by the end of March 2022. Prior to 28
80	March, all pediatric COVID-19 cases notified in Shanghai were referred to the designated hospital for
81	concentrating management and isolation. Since 28 March when a large number of cases were confirmed
82	by massive screening test, most of asymptomatic and mild pediatric cases aged 5-17 years were almost
83	sent to Fangcang shelter hospitals. All confirmed cases irrespective of symptoms are required for in-
84	hospital isolation and are discharged if the cycle threshold (Ct) value for the viral nucleic acid is great
85	than 35 on PCR test for the two consecutive respiratory samples taken 24-hour apart [15].
86	Case definition and classification
87	All COVID19 cases were laboratory-confirmed by the Shanghai CDC reference laboratory using
88	real-time RT-PCR commercial kit. The Ct value <40 was defined as a positive nucleic acid amplification
89	test. COVID-19 cases were classified as asymptomatic and symptomatic cases. Symptomatic cases were
90	classified as mild, moderate and severe cases. An asymptomatic case is defined as a person with a positive
91	nucleic acid test but without any clinical symptom of COVID-19. A confirmed symptomatic case is

92	defined as a person presenting clinical signs and symptoms of COVID-19. COVID-19 disease severity
93	classification is based on the WHO guidance [16]. Pneumonia was diagnosed based on clinical signs
94	(fever and/or cough accompanying with one of the following signs: moist rales on auscultation, difficulty
95	breathing/dyspnoea, fast breathing, chest indrawing), radiological findings compatible with pneumonia.
96	Data collection
97	Data were collected via a face-to-face interview with parents or teenagers and electronic medical
98	chart, including: demographic information, epidemiological exposure setting, COVID-19 vaccination
99	status on dose and date, clinical symptoms, laboratory findings and chest imaging if examined, treatment
100	and outcome. Informed consent from parents was not required by the ethics committee because all data
101	were de-identified and not involved in personal privacy.

102 Statistical analysis

103 Data was entered into Excel version 2016 (Microsoft, Redmond, Washington) for analysis and the 104 statistical analysis was preformed using SPSS (IBM Statistic 23.0). Categorical variables are described 105 as absolute numbers and percentage. Continuous variables with normal distribution are expressed as 106 mean  $\pm$  standard deviation. Median (25% to 75% interquartile range (IQR) are used when the frequency 107 distributions were skewed. Differences between groups are compared using Mann-Whitney U-test and 108 Student's t-test as appropriate. A difference with P < 0.05 is considered to be statistically significant. 109 Relative risks (RR) were calculated using proportion of symptomatic infection and febrile cases by 110 vaccination status, with the referent group being  $\geq$ 2-dose vaccinees.

111 **Results** 

# 112 **Demographic characteristics**

113The first local pediatric case was notified on March 2022 and increased remarkably from 14 March114onwards (as shown in Figure 1). As of 31 March, a total of 376 pediatric cases of COVID-19 were

115	referred to the exclusively designated hospital. The ratio of male-to-female was 1.1 (206/170). The 376
116	cases were aged 11 days-17 years with the median age of 5.0 years (IQR: 2, 9) and the mean age of
117	6.0±4.2 years: 28 (7.4%) cases in age group <1 year, 76 (20.2%) cases in age group 1-2 years, 94 (25.0%)
118	cases in age group 3-5 years, 134 (35.6%) cases in age group 6-11 years, and 44 (11.7%) cases in age
119	group $\geq 12$ years.
120	Epidemiological exposure
121	Three hundred and seven (81.6%) cases had a clear history of exposure, of whom, 213 (69.1%)
122	had a close contact with confirmed adult cases in household, 67 (21.8%) had a clear contact with
123	confirmed child cases in school, and 27 (8.8%) had an epidemiological linkage to residential area
124	where cluster cases of COVID-19 were reported. As shown in Figure 2, the first child case acquired
125	infection in family, soon after, child cases linked to possible community transmission were found, who
126	had no clear exposure.
127	Vaccination status
128	A total of 126 had received at least one dose of an inactivated COVID-19 vaccine, accounting for
129	33.5% of the total 376 pediatric cases and 46.3% of the 272 pediatric cases aged $\geq$ 3 years eligible for
130	COVID-19 vaccination in China. Of the 272 vaccine-eligible children, 146 (53.6%) were unvaccinated,
131	110 (40.4%) had received 2 doses and 16 (4.0%) had received 1 dose. Among the 94 preschool children
132	aged 3-5 years, the proportions of 1 dose and 2 doses of COVID-19 vaccination were 3.2% (3/94) and
133	5.3% (5/94), respectively. Among the 178 school children aged 6-17 years, the proportions of 1 dose and
134	2 doses of COVID-19 vaccination were 7.3% (13/174) and 59.0% (105/174), respectively. Overall, the
135	interval between vaccination and breakthrough infection ranged from 16 days to 7 months (median: 3.5
136	(IQR: 3, 4.5) months).

As shown in table 1, 2-dose COVID-19 vaccination reduced the risk of symptomatic infection and

138	febrile disease by 35% (0.65, 95% CI: 0.53-0.79) and by 36% (RR 0.64, 95% CI: 0.51-0.81) in children
139	0-17 years, by 29% (RR 0.71, 95% CI: 0.57-0.88) and 29% (RR 0.71, 95% CI: 0.55-0.92) in children 3-
140	17 years eligible for COVID-19 vaccine. However, one-dose vaccination could not significantly decrease
141	the relative risks of symptomatic infection and febrile disease.
142	Clinical manifestation and course
143	Of the 376 cases, 257 (68.4%) presented symptoms and 119 (31.6%) had no symptoms before and
144	duration hospitalization. Of the 257 symptomatic cases, 216 (83.4%) experienced fever (axillary
145	temperature >37.5°C) with a mean fever spike of 38.9± 0.6°C (range: 37.6-41°C) and a mean fever
146	duration of 1.7±1.0.8 days (range: 0.5-4 days), 104 (40.2%) presented cough, 28 (10.8%) self-reported
147	sore throat, 13 (5.0%) self-reported stuffy nose, 6 (2.3%) had runny nose, 11 (4.2%) had nausea or
148	vomiting or diarrhea, 2 (0.8%) self-reported transient loss of taste and smell. No severe case was
149	diagnosed. Twenty five cases had chest CT performed due to fever >38.5°C lasting for 3 days or cough
150	worsening after admission or routine examination prior to the referral. The chest images showed patchy
151	infiltrates or ground-glass opacity in 4 cases and one of them was right lung lobar pneumonia caused by
152	Mycoplasma pneumoniae. Six (1.6%) cases had comorbidity including brain tumor, febrile seizure,
153	psychomotor retardation, hemophilia, Henoch-Schonlein purpura, and cardiac arrhythmia in each.
154	As shown in table 2, 22.8% (57/250) of unvaccinated cases were asymptomatic while 50.0%
155	(55/110) of 2-dose vaccinated cases were asymptomatic (P=0.000); 65.2% (163/250) of unvaccinated
156	cases were febrile while 41.8%% (46/110) of 2-dose vaccinated cases were febrile (P=0.000).
157	Symptomatic infection was significantly frequently seen in the age group <3 years than in the age group
158	3-5 years (P=0.003) and 6-17 years (P=0.000). Fever was significantly frequently seen in the age group

3-5 years than in the age group <3 years (P=0.000) and 6-17 years (P=0.005).

160 Of the 225 case who had complete peripheral blood cell count tested, 37 (16.4%) had white blood 161 cell (WBC) count  $<4\times10^{9}/L$ , 173 (76.9%) had WBC count 4-9 $\times10^{9}/L$ , 13 (5.8%) had WBC count 10- $14 \times 10^{9}$ /L and 2 (7.1%) had WBC count  $\geq 15 \times 10^{9}$ /L. The WBC count ranged from  $1.9 \times 10^{9}$ /L to 162 163 15.5×10<sup>9</sup>/L. No thrombopenia was observed. Of the 187 cases who had peripheral blood C-reactive 164 protein (CRP) tested, 178 (95.2%) had CRP <8 mg/L, 8 (4.3%) had CRP >8 mg/L (range: 8.8-35.8 mg/L) 165 and 1 (0.5%) had CRP 56 mg/L who had co-infection with mycoplasma pneumoniae and developed 166 typical lobar pneumonia in right lung. Of the 196 cases who had serum biochemical markers and 8 (4.1%) 167 showed slightly elevated liver enzyme. 168 For symptomatic cases, Ibuprofen and or Chinese traditional medicines were prescribed depending 169 on the personalized condition and medication compliance. Only one case who had a clear diagnosis of 170 mycoplasma pneumonia was prescribed antibiotics. All cases were discharged when the Ct value of the 171 nucleic acid of SARS-CoV-2 virus reached >35. The average duration of Ct value of the nucleic acid of 172 SARS-CoV-2 virus >35 since admission was  $11.7\pm3.7$  days (range: 3-25 days; symptomatic verse 173 asymptomatic: 11.7±3.6 verse 11.7±3.9, P=0.064). 174

# 175 Discussion

This study first presents the epidemiological and clinical profiles of Omicron variant infection in localized children during the early phase of outbreak in Shanghai. As of 31 March 2022, all pediatric COVID-19 cases were mild (68.4%) or asymptomatic (31.6%). However, a few of severe pediatric cases were reported during the period of COVID-19 outbreak in Wuhan in early 2020 [17]. Moreover, the proportion of asymptomatic cases was 2-time more than that seen in the Wuhan outbreak. We reason that

181 high coverage of COVID-19 vaccination among Shanghainese children is very likely to lower the risk of 182 severe Omicron infection-associated disease. The mass COVID-19 vaccination roll-out among children 183 3-17 years started between Mid-Aug 2021 and December 2021 in Shanghai and the estimated coverage 184 rate of 2-dose COVID-19 vaccination among children 3-17 years has exceeded 70% by of the end of 185 March in 2022. In this case cohort 46.3% of children eligible for COVID-19 vaccination prior to 16 days 186 to 7 months (median: 3.5months). Observational studies from some countries with the high levels of 187 population immunity generated by natural infection or vaccine have shown receipt of two doses of 188 COVID-19 vaccines and a booster dose can offer protection against symptomatic and severe Omicron 189 infection in a short-term period of vaccination [4,18-22]. 190 Current evidences consistently show a reduction in neutralizing antibody against Omicron in serum 191 of convalescent or vaccinated individuals, resulting in Omicron's immune escape potential against 192 vaccine- and infection-induced immunity [4,23]. However, two recent study based on real-world 193 observation among children showed the modest effectiveness for COVID-19 vaccine against Omicron 194 infection [25,26]. Based on our findings, receipt of 2-dose inactivated COVID-19 vaccine within 17 days 195 to 7 months after fully primary vaccination potentially reduced the risk of symptomatic Omicron infection by 31% and febrile disease by 59% in children. We did not estimate vaccine protection against 196 197 severe infection because no severe COVID-19 cases were diagnosed. There is also evidence of waning 198 of vaccine effectiveness over time of the primary series against infection and symptomatic disease for 199 the studied vaccines. However, the vaccine effectiveness against Omicron infection and disease can be 200 restored and increase to > 40% to 80% within a short follow-up time after a third booster dose in studies 201 from five countries (United Kingdom, Denmark, Canada, South Africa, USA) [4]. Ten cases of 202 reinfection with Omicron variant were identified within 23 to 87 days of a previous Delta infection was

203	reported in the USA and most were pediatric cases [26]. Thus, eligible children and adolescents should
204	remain up to date with recommended COVID-19 vaccination in response to Omicron outbreak. So far, a
205	third booster dose of COVID-19 vaccine has been recommended for use in adults but not in children in
206	China. In light of the field findings, a booster dose should also be recommended for eligible children 3-
207	17 years.
208	We observed that school children aged 6-11 years comprised the most cases, followed by home-care
209	children <2 years and preschool children 3-5 year. The distribution of age groups in the early stage of
210	outbreak reflects the cluster transmission of COVID-19 centered in elementary school, kindergarten, and
211	household. Of note, age group 12-17 years accounted for the smallest proportion of pediatric cases,
212	among which, the high coverage rate of COVID-19 vaccination was as high as 95%. Based on the
213	epidemiological investigation, more than 80% children had a clear history of exposure, mostly occurring
214	in family (69.1%) and school (21.8%), occasionally in residential area (8.8%). The remaining 18.4% of
215	children had no clear contact with confirmed cases, reflecting small-scale community transmission had
216	already appeared prior to the large-scale outbreak since April. During the 2020 outbreak of COVID-19,
217	80%-90% of confirmed child cases were family cluster cases and community transmission was unusual
218	in China [17,27]. Rapid increases in pediatric COVID-19 cases and epidemiological unrelated cases also
219	suggest the occurrence of high community transmission of Omicron variant in Shanghai since the early
220	epidemic wave.
221	We observed most of localized pediatric cases (83.4%) of symptomatic Omicron infection
222	presenting fever. However, fever is less commonly seen in pediatric COVID-19 cases reported in China
223	(58%) and the USA (56%) during the first wave of pandemic in 2020 [10, 17]. Fever could be helpful for

224 early recognition and diagnosis of COVID-19 because parents always worry about the febrile child and

225 visit hospital for seeking medical care. The febrile course of Omicron infection is brief with a mean fever 226 duration of 1.7±1.0.8 days, significantly shorter than fever duration seen influenza (4 days) [28]. The 227 febrile duration is helpful to differentiate COVID-19 from influenza in children when the epidemics of 228 COVID-19 and influenza overlap. 229 The potential role in transmission for most asymptomatic and mild child cases should not be 230 neglected. A study showed that symptomatic and asymptomatic children can carry high quantities of live 231 SARS-CoV-2, creating a potential reservoir for transmission [29]. Vaccinees with mild or asymptomatic 232 Omicron infection shed infectious virus 6-9 days after onset or diagnosis, even after symptom resolution 233 [30]. In fact, asymptomatic infection in children was underestimated in the early stage of outbreak 234 because massive screening of COVID-19 cases had not been carried out before 28 March. After citywide 235 large-scale screening, notifiable asymptomatic cases accounted for 90% more or less in April. 236 Asymptomatic infection was much more common in vaccinated children than in unvaccinated children 237 (50% vs 22.8%). Vaccination can offer protection against symptomatic infection and febrile disease, on 238 the other hand, the role of asymptomatic children play in viral transmission is of attention during outbreak. 239 High prevalence of asymptomatic infection is likely a major factor in the widespread of the Omicron 240 variant among population. 241 In summary, COVID-19 is mild and subtle in Shanghainese children with the high level of vaccine-

induced immunity during the early stage of Omicron outbreak. COVID-19 vaccination can offer partial protection against symptomatic COVID-19. Ongoing Omicron epidemic will increase the risk of exposure among children with underlying medical conditions, who are usually unvaccinated, therefore, severe COVID-19 infection is anticipated to be encountered in children. Non-pharmaceutical interventions in combination with vaccination strategies are critical to prevent infection and severe 247 disease and to mitigate the impact of COVID-19 in pediatric population.

# 248 Transparency declaration

- 249 The authors have declared that there are no conflicts of interest in relation to this work. Disclosure forms
- 250 provided by the authors are available as Supplementary material.
- 251 Funding
- 252 This work was supported by the Science and Technology Commission of Shanghai Municipality (NO.
- 253 20JC141020002), the Key Development Program of Children's Hospital of Fudan University
- 254 (EK2022ZX05), the Three-Year Action Plan for Strengthening the Construction of Public Health System
- 255 in Shanghai (2020-2022) (GWV-3.2), and the Key Discipline Construction Plan from Shanghai
- 256 Municipal Health Commission (GWV-10.1-XK01). None of the funding organizations played any role
- 257 in the trial design, data collection, analysis of results, or writing of the manuscript.

# 258 Author contributions

- 259 Conceptualization: YZ, XZ, MZ; Methodology: XW, HC, HT, MZ; Software: XW, HC, HT; Validation:
- 260 JC; Formal Analysis: XW, HC, HT, YZ, MZ; Investigation: JL, ZW, YW, AX, YG, JW, GL, JC; Writing-
- 261 Original Draft: XW, HC, YZ, MZ; Writing-Review & Editing: XW, MZ; Visualization: JC, HC;
- 262 Supervision: YZ, GL, JW, QZ, XZ, MZ; Project Administration: XZ; Funding acquisition: XZ, MZ. All
- authors approved the manuscript for publication.
- 264

#### 265 Reference

- 266 1. World Health Organization. COVID-19 disease in children and adolescents: Scientific brief, 29
- 267 September 2021. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-Sci Brief-
- 268 Children\_and\_adolescents-2021.1. [Accessed 18 April 2022].

269	2. World Health Organization. Pulse survey on continuity of essential health services during the
270	COVID-19 pandemic: interim report, 27 August 2020. Available from:
271	https://www.who.int/publications/i/item/WHO-2019-nCoV-EHS_continuity-survey-2020.1. [Accessed
272	18 April 2022].
273	3. Meherali S, Punjani N, Louie-Poon S, Abdul Rahim K, Das JK, Salam RA, et al. Mental Health of
274	Children and Adolescents Amidst COVID-19 and Past Pandemics: A Rapid Systematic. Review Int J
275	Environ Res Public Health 2021;18(7):3432. https://doi.org/10.3390/ijerph18073432
276	4. World Health Organization. Enhancing response to Omicron SARS-CoV-2 variant: Technical brief
277	and priority actions for Member States. Available at:
278	https://www.who.int/publications/m/item/enhancing-readiness-for-omicron-(b.1.1.529)-technical-brief-
279	and-priority-actions-for-member-states. [Accessed 22 April 2022].
280	5. World Health Organization. Weekly epidemiological update on COVID-19 - 1 March 2022. Available
281	from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-191-
282	march-2022. [Accessed 22 April 2022].
283	6. Iuliano AD, Brunkard JM, Boehmer TK, Peterson E, Adjei S, Binder AM, et al. Trends in Disease
284	Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous
285	SARS-CoV-2 High Transmission Periods - United States, December 2020-January 2022. MMWR Morb
286	Mortal Wkly Rep 2022;71(4):146-52. https://doi.org/10.15585/mmwr.mm7104e4
287	7. American Academy of Pediatrics, Children's Hospital Association. Children and COVID-19:
288	State Data Report (Version3/31/22). Available from: https://www.aap.org/en/pages/2019-novel-
289	coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report/ [Accessed 22 April
290	2022].

- 8. World Health Organization (WHO). 2020. Report of the WHO-China joint mission on coronavirus
- disease 2019 (covid-19). Available from: https://www.who.int/publications/i/item/report-of-the-who-
- 293 china-joint-mission-on-coronavirus-disease-2019-(covid-19). [Accessed 21 April 2022].
- 294 9. Choi SH, Kim HW, Kang JM, Kim DH, Cho EY. 2020. Epidemiology and clinical features of
- 295 coronavirus disease 2019 in children. Clin Exp Pediatr 63;(4):125-32.
- 296 https://doi.org/10.3345/cep.2020.00535
- 297 10. CDC COVID-19 Response Team. Coronavirus Disease 2019 in Children United States, February
- 298 12-April 2, 2020. MMWR Morb Mortal Wkly Rep 2020;69(14):422-6.
- 299 https://doi.org/10.15585/mmwr.mm6914e4
- 300 11. Ladhani SN, Amin-Chowdhury Z, Davies HG, Aiano F, Hayden I, Lacy J, et al. COVID-19 in
- 301 children: analysis of the first pandemic peak in England. Arch Dis Child 2020;105(12):1180-5.
- 302 https://doi.org/10.1136/archdischild-2020-320042
- 303 12. Malcangi G, Inchingolo AD, Inchingolo AM, Piras F, Settanni V, Garofoli G, et al. COVID-19
- 304 Infection in Children and Infants: Current Status on Therapies and Vaccines. Children (Basel).
- 305 2022;9(2):249. https://doi.org/10.3390/children9020249
- 306 13. Singhal T. The Emergence of Omicron: Challenging Times Are Here Again! Indian J Pediatr
- 307 2022;89(5):490-6. https://doi.org/10.1007/s12098-022-04077-4
- 308 14. Smith DJ, Hakim AJ, Leung GM, Xu WB, Schluter WW, Novak RT, et al. Preplanned Studies:
- 309 COVID-19 Mortality and Vaccine Coverage Hong Kong Special Administrative Region, China, January
- 310 6, 2022–March 21, 2022. China CDC Weekly 2022; 4(14): 288-92.
- 311 https://doi.org/10.46234/ccdcw2022.071
- 312 15. National Health Commission of The People's Republic of China. Interim protocol of diagnosis and

- 313 treatment of 2019 novel coronavirus-associated pneumonia (the nineth version). Available from:
- 314 http://www.gov.cn/zhengce/zhengceku/2022-03/15/content 5679257.htm. [Accessed 22 April 2022].
- 315 16. World Health Organization. Living guidance for clinical management of COVID-19. Available at:
- 316 https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-2. [Accessed 22 April 2022].
- 317 17. Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, et al. Chinese Pediatric Novel Coronavirus Study
- 318 Team. SARS-CoV-2 Infection in Children. N Engl J Med 2020;382(17):1663-5.
- 319 https://doi.org/10.1056/NEJMc2005073
- 320 18. Cloete J, Kruger A, Masha M, du Plessis NM, Mawela D, Tshukudu M, et al. Paediatric
- 321 hospitalisations due to COVID-19 during the first SARS-CoV-2 omicron (B.1.1.529) variant wave
- in South Africa: a multicentre observational study. Lancet Child Adolesc Health 2022;6(5):294-302.
- 323 https://doi.org/10.1016/S2352-4642(22)00027-X
- 324 19. Wang L, Berger NA, Kaelber DC, Davis PB, Volkow ND, Xu R. Incidence Rates and Clinical
- 325 Outcomes of SARS-CoV-2 Infection with the Omicron and Delta Variants in Children Younger than
- 326 5 Years in the US. JAMA Pediatr 2022;1:e220945.
- 327 https://doi.org/10.1001/jamapediatrics.2022.0945
- 328 20. I Iuliano AD, Brunkard JM, Boehmer TK, Peterson E, Adjei S, Binder AM, et al. Trends in Disease
- 329 Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous
- 330 SARS-CoV-2 High Transmission Periods United States, December 2020-January 2022. MMWR Morb
- 331 Mortal Wkly Rep 2022;71(4):146-52. https://doi.org/10.15585/mmwr.mm7104e4
- 332 21. Menni C, Valdes AM, Polidori L, Antonelli M, Penamakuri S, Nogal A, et al. Symptom
- 333 prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2
- during periods of omicron and delta variant dominance: a prospective observational study from the

335 ZOE COVID Study. Lancet 2022;7:S0140-6736(22)00327-0. https://doi.org/10.1016/S0140336 6736(22)00327-0

- 22. Wolter N, Jassat W, Walaza S, Welch R, Moultrie H, Groome M, et al. Early assessment of the
- 338 clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet
- 339 2022;399(10323):437-46. https://doi.org/10.1016/S0140-6736(22)00017-4
- 340 23. Peiris M, Cheng S, Mok CKP, Leung Y, Ng S, Chan K, et al. Neutralizing antibody titres to SARS-
- 341 CoV-2 Omicron variant and wild-type virus in those with past infection or vaccinated or boosted with
- 342 mRNA BNT162b2 or inactivated CoronaVac vaccines. Res Sq [Preprint] 2022;rs.3.rs-1207071.
- 343 https://doi.org/10.21203/rs.3.rs-1207071/v1
- 24. Fowlkes AL, Yoon SK, Lutrick K, Gwynn L, Burns J, Grant L, et al. Effectiveness of 2-Dose
- 345 BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among
- 346 Children Aged 5-11 Years and Adolescents Aged 12-15 Years PROTECT Cohort, July 2021-
- 347 February 2022. MMWR Morb Mortal Wkly Rep. 2022 Mar 18;71(11):422-8.
- 348 https://doi.org/10.15585/mmwr.mm7111e1
- 349 25. Araos R, Jara A, Undurraga E, Zubizarreta J, Gonzalez C, Acevedo J, et al. Effectiveness of
- 350 CoronaVac in children 3 to 5 years during the omicron SARS-CoV-2 outbreak. Research Square
- 351 [Preprint]. https://doi.org/10.21203/rs.3.rs-1440357/v1
- 26. Roskosky M, Borah BF, DeJonge PM, Donovan CV, Blevins LZ, Lafferty AG, et al. Notes
- 353 from the Field: SARS-CoV-2 Omicron Variant Infection in 10 Persons Within 90 Days of Previous
- 354 SARS-CoV-2 Delta Variant Infection Four States, October 2021-January 2022. MMWR Morb
- 355 Mortal Wkly Rep 2022;71(14):524-6. https://doi.org/10.15585/mmwr.mm7114a2
- 27. Jiehao C, Jin X, Daojiong L, Zhi Y, Lei X, Zhenghai Q, et al. A Case Series of Children With

- 357 2019 Novel Coronavirus Infection: Clinical and Epidemiological Features. Clin Infect Dis
- 358 2020;71(6):1547-51. https://doi.org/10.1093/cid/ciaa198
- 28. Wang X, Cai J, Yao W, Zhu Q, Zeng M. Socio-economic impact of influenza in children:a
- 360 single-centered hospital study in Shanghai. Chin J Epidemiol 2015;36(1):27-30.
- 361 29. Yonker LM, Boucau J, Regan J, Choudhary MC, Burns MD, Young N, et al. Virologic Features of
- 362 Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children. J Infect Dis
- 363 2021;224(11):1821-9. https://doi.org/10.1093/infdis/jiab509
- 364 30. Takahashi K, Ishikane M, Ujiie M, Iwamoto N, Okumura N, Sato T, et al. Duration of
- 365 Infectious Virus Shedding by SARS-CoV-2 Omicron Variant-Infected Vaccinees. Emerg Infect Dis
- 366 2022;28(5):998-1001. https://doi.org/10.3201/eid2805.220197

Vaccination status by age group (years)	Symptomatic case, n (%)	Relative risk (95% CI)	Febrile cases n (%)	Relative risk (95% CI)
0-17 (n=376)				
unvaccinated (n=250)	193 (77.2%)	ref	163 (65.2%)	ref
1 dose (n=16)	9 (56.3%)	0.73 (0.47-1.13)	7 (43.8%)	0.67 (0.38-1.18)
2 doses (n=110)	55 (50.0%)	0.65 (0.53-0.79)	46 (41.8%)	0.64 (0.51-0.81)
3-17 (n=272)				
unvaccinated (n=146)	103 (70.5%)	ref	86 (58.9%)	ref
1 dose (n=16)	9 (56.3%)	0.80 (0.51-1.24)	7 (43.8%)	0.74 (0.42-1.32)
2 doses (n=110)	55 (50.0%)	0.71(0.57-0.88)	46 (41.8%)	0.71 (0.55-0.92)

368	Table 1. Clinical characteristics of SARS-CoV-2 infection according to COVID-19 vaccination
369	status

**Abbreviation:** ref = referent group.

	Total (n=376)	Age group (years)			Vaccination status		P value	
Clinical characteristics		<3 3-5 6-17 <i>P</i> value		P value	Unvaccinated 2-dose vaccination			
		(n=104)	(n=104) (n=94) (n=178)		(n=250) (n=110)	(n=110)		
Asymptomatic	119	14	29	76	0	57 (22.8%)	55 (50.0%)	0
cases, n (%)	(31.6%)	(13.5%)	(30.9%)	(42.7%)				0
Symptomatic	257	90	65	102	0	102 (55 20/)		0
cases, n (%)	(68.4%)	(86.5%)	(69.1%)	(57.3%)	0	193 (77.2%)	55 (50.0%)	0
Febrile cases,	216	44	59	80	0.000	1 (2 ((5 20))		0
n (%)	(57.4%)	(42.3%)	(62.8%)	(44.9%)	0.006	163 (65.2%)	46 (41.8%)	0
Fever spike								
(°C), mean±SD	38.9±0.6	39.0±0.7	39.0±0.6	38.8±0.6	0.064	38.9±0.6	38.8±0.7	0.27
Fever duration	1.7±0.8	1700	1 ( ) 0 (	1.0+0.0	0.45	1 ( 0 9	1000	0.10
(days), mean±SD		1.7±0.9	1.6±0.6	1.8±0.8	0.45	1.6±0.8	1.9±0.9	0.19

Table 2. Clinical characteristics of SARS-CoV-2 virus infection by age group




Figure 1. Daily COVID-19 cases referred to the designated hospital for children aged <18 years from March 1 to March 31, 2022




Figure 2. Model of epidemiological exposure over time among pediatric COVID-19 cases